A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Identifieur interne : 001498 ( Main/Corpus ); précédent : 001497; suivant : 001499A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Auteurs : E. Maillart ; S. Leemans ; H. Van Noten ; T. Vandergraesen ; B. Mahadeb ; M T Salaouatchi ; D. De Bels ; P. ClevenberghSource :
- Infectious diseases (London, England) [ 2374-4243 ] ; 2020.
English descriptors
- KwdEn :
- Aged (MeSH), Azithromycin (therapeutic use), Betacoronavirus (genetics), Betacoronavirus (isolation & purification), Blood Transfusion (MeSH), COVID-19 (MeSH), Continuous Renal Replacement Therapy (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Drug Therapy, Combination (MeSH), Enzyme Inhibitors (adverse effects), Enzyme Inhibitors (therapeutic use), Glucosephosphate Dehydrogenase Deficiency (complications), Haptoglobins (analysis), Hemolysis (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Hypoxia (chemically induced), Hypoxia (complications), Male (MeSH), Nasopharynx (virology), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Respiratory Distress Syndrome (complications), SARS Virus (genetics), SARS Virus (isolation & purification), SARS-CoV-2 (MeSH).
- MESH :
- chemical , adverse effects : Enzyme Inhibitors, Hydroxychloroquine.
- chemical , analysis : Haptoglobins.
- chemical , therapeutic use : Azithromycin, Enzyme Inhibitors, Hydroxychloroquine.
- chemically induced : Hypoxia.
- complications : Coronavirus Infections, Glucosephosphate Dehydrogenase Deficiency, Hypoxia, Pneumonia, Viral, Respiratory Distress Syndrome.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- genetics : Betacoronavirus, SARS Virus.
- isolation & purification : Betacoronavirus, SARS Virus.
- virology : Nasopharynx.
- Aged, Blood Transfusion, COVID-19, Continuous Renal Replacement Therapy, Drug Therapy, Combination, Hemolysis, Humans, Male, Pandemics, SARS-CoV-2.
Abstract
While the COVID-19 epidemic occurred since December 2019, as of end April 2020, no treatment has been validated or invalidated by accurate clinical trials. Use of hydroxychloroquine has been popularised on mass media and put forward as a valid treatment option without strong evidence of efficacy. Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Side effects may be worse than the disease itself. Belgian national treatment guidelines recommend the use of HCQ in mild to severe COVID-19 disease. As opinions, politics, media and beliefs are governing COVID-19 therapy, performance of randomised controlled blinded clinical trials became difficult. Results of sound clinical trials are eagerly awaited. We report a case of acute haemolysis leading to admission in intensive care unit and renal failure in a patient with uncovered G6PD deficiency.
DOI: 10.1080/23744235.2020.1774644
PubMed: 32496938
PubMed Central: PMC7284136
Links to Exploration step
pubmed:32496938Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.</title><author><name sortKey="Maillart, E" sort="Maillart, E" uniqKey="Maillart E" first="E" last="Maillart">E. Maillart</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Leemans, S" sort="Leemans, S" uniqKey="Leemans S" first="S" last="Leemans">S. Leemans</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Van Noten, H" sort="Van Noten, H" uniqKey="Van Noten H" first="H" last="Van Noten">H. Van Noten</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Vandergraesen, T" sort="Vandergraesen, T" uniqKey="Vandergraesen T" first="T" last="Vandergraesen">T. Vandergraesen</name><affiliation><nlm:affiliation>Internal Medicine Department, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Mahadeb, B" sort="Mahadeb, B" uniqKey="Mahadeb B" first="B" last="Mahadeb">B. Mahadeb</name><affiliation><nlm:affiliation>Brussels Academic Hospital Laboratory, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Salaouatchi, M T" sort="Salaouatchi, M T" uniqKey="Salaouatchi M" first="M T" last="Salaouatchi">M T Salaouatchi</name><affiliation><nlm:affiliation>Internal Medicine Department, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="De Bels, D" sort="De Bels, D" uniqKey="De Bels D" first="D" last="De Bels">D. De Bels</name><affiliation><nlm:affiliation>Intensive Care Unit, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Clevenbergh, P" sort="Clevenbergh, P" uniqKey="Clevenbergh P" first="P" last="Clevenbergh">P. Clevenbergh</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32496938</idno><idno type="pmid">32496938</idno><idno type="doi">10.1080/23744235.2020.1774644</idno><idno type="pmc">PMC7284136</idno><idno type="wicri:Area/Main/Corpus">001498</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001498</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.</title><author><name sortKey="Maillart, E" sort="Maillart, E" uniqKey="Maillart E" first="E" last="Maillart">E. Maillart</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Leemans, S" sort="Leemans, S" uniqKey="Leemans S" first="S" last="Leemans">S. Leemans</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Van Noten, H" sort="Van Noten, H" uniqKey="Van Noten H" first="H" last="Van Noten">H. Van Noten</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Vandergraesen, T" sort="Vandergraesen, T" uniqKey="Vandergraesen T" first="T" last="Vandergraesen">T. Vandergraesen</name><affiliation><nlm:affiliation>Internal Medicine Department, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Mahadeb, B" sort="Mahadeb, B" uniqKey="Mahadeb B" first="B" last="Mahadeb">B. Mahadeb</name><affiliation><nlm:affiliation>Brussels Academic Hospital Laboratory, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Salaouatchi, M T" sort="Salaouatchi, M T" uniqKey="Salaouatchi M" first="M T" last="Salaouatchi">M T Salaouatchi</name><affiliation><nlm:affiliation>Internal Medicine Department, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="De Bels, D" sort="De Bels, D" uniqKey="De Bels D" first="D" last="De Bels">D. De Bels</name><affiliation><nlm:affiliation>Intensive Care Unit, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Clevenbergh, P" sort="Clevenbergh, P" uniqKey="Clevenbergh P" first="P" last="Clevenbergh">P. Clevenbergh</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Infectious diseases (London, England)</title><idno type="eISSN">2374-4243</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (genetics)</term><term>Betacoronavirus (isolation & purification)</term><term>Blood Transfusion (MeSH)</term><term>COVID-19 (MeSH)</term><term>Continuous Renal Replacement Therapy (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Therapy, Combination (MeSH)</term><term>Enzyme Inhibitors (adverse effects)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Glucosephosphate Dehydrogenase Deficiency (complications)</term><term>Haptoglobins (analysis)</term><term>Hemolysis (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Hypoxia (chemically induced)</term><term>Hypoxia (complications)</term><term>Male (MeSH)</term><term>Nasopharynx (virology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Respiratory Distress Syndrome (complications)</term><term>SARS Virus (genetics)</term><term>SARS Virus (isolation & purification)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Haptoglobins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azithromycin</term><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypoxia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Glucosephosphate Dehydrogenase Deficiency</term><term>Hypoxia</term><term>Pneumonia, Viral</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Betacoronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Nasopharynx</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Blood Transfusion</term><term>COVID-19</term><term>Continuous Renal Replacement Therapy</term><term>Drug Therapy, Combination</term><term>Hemolysis</term><term>Humans</term><term>Male</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">While the COVID-19 epidemic occurred since December 2019, as of end April 2020, no treatment has been validated or invalidated by accurate clinical trials. Use of hydroxychloroquine has been popularised on mass media and put forward as a valid treatment option without strong evidence of efficacy. Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Side effects may be worse than the disease itself. Belgian national treatment guidelines recommend the use of HCQ in mild to severe COVID-19 disease. As opinions, politics, media and beliefs are governing COVID-19 therapy, performance of randomised controlled blinded clinical trials became difficult. Results of sound clinical trials are eagerly awaited. We report a case of acute haemolysis leading to admission in intensive care unit and renal failure in a patient with uncovered G6PD deficiency.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32496938</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-4243</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Infectious diseases (London, England)</Title><ISOAbbreviation>Infect Dis (Lond)</ISOAbbreviation></Journal><ArticleTitle>A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.</ArticleTitle><Pagination><MedlinePgn>659-661</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/23744235.2020.1774644</ELocationID><Abstract><AbstractText>While the COVID-19 epidemic occurred since December 2019, as of end April 2020, no treatment has been validated or invalidated by accurate clinical trials. Use of hydroxychloroquine has been popularised on mass media and put forward as a valid treatment option without strong evidence of efficacy. Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Side effects may be worse than the disease itself. Belgian national treatment guidelines recommend the use of HCQ in mild to severe COVID-19 disease. As opinions, politics, media and beliefs are governing COVID-19 therapy, performance of randomised controlled blinded clinical trials became difficult. Results of sound clinical trials are eagerly awaited. We report a case of acute haemolysis leading to admission in intensive care unit and renal failure in a patient with uncovered G6PD deficiency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maillart</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leemans</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Noten</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandergraesen</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahadeb</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Brussels Academic Hospital Laboratory, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salaouatchi</LastName><ForeName>M T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bels</LastName><ForeName>D</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9324-5768</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clevenbergh</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Clinic, University Hospital Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis (Lond)</MedlineTA><NlmUniqueID>101650235</NlmUniqueID><ISSNLinking>2374-4243</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006242">Haptoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079664" MajorTopicYN="N">Continuous Renal Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005955" MajorTopicYN="N">Glucosephosphate Dehydrogenase Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006242" MajorTopicYN="N">Haptoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006461" MajorTopicYN="Y">Hemolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Covid-19</Keyword><Keyword MajorTopicYN="Y">adverse event</Keyword><Keyword MajorTopicYN="Y">evidence-based medicine</Keyword><Keyword MajorTopicYN="Y">glucose-6-phosphate dehydrogenase (G6PD) deficiency</Keyword><Keyword MajorTopicYN="Y">haemolysis</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32496938</ArticleId><ArticleId IdType="doi">10.1080/23744235.2020.1774644</ArticleId><ArticleId IdType="pmc">PMC7284136</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Infez Med. 2020 Ahead of print Jun 1;28(2):198-211</Citation><ArticleIdList><ArticleId IdType="pubmed">32335561</ArticleId></ArticleIdList></Reference><Reference><Citation>Australas J Dermatol. 2020 May;61(2):e150-e157</Citation><ArticleIdList><ArticleId IdType="pubmed">31612996</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation><ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2018 Mar;70(3):481-485</Citation><ArticleIdList><ArticleId IdType="pubmed">28556555</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2020 Jul;123:120-126</Citation><ArticleIdList><ArticleId IdType="pubmed">32330521</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2020 Jun 1;130(6):2752-2753</Citation><ArticleIdList><ArticleId IdType="pubmed">32330122</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Haematol. 2020 Sep;105(3):357-359</Citation><ArticleIdList><ArticleId IdType="pubmed">32324284</ArticleId></ArticleIdList></Reference><Reference><Citation>MSMR. 2019 Dec;26(12):14-17</Citation><ArticleIdList><ArticleId IdType="pubmed">31860324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001498 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001498 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32496938
|texte= A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32496938" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |